Patent Examiner Sean E. Aeder
Art Unit 1642 · Antibodies, Cancer Immunotherapy & Diagnostics · Tech Center 1600 · 332 applications filed 2021–2026
Sean E. Aeder is a USPTO patent examiner in Art Unit 1642 (Antibodies, Cancer Immunotherapy & Diagnostics) with 332 applications from filing years 2021–2026. Examiner Aeder's allowance rate is 58.3%, below the 82.4% USPTO average for applications filed in the same years. The examiner ranks harder than 84% of examiners. In 2021, decided applications with an examiner interview were allowed 41.4 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1642 · Antibodies, Cancer Immunotherapy & Diagnostics
- Title / gradePrimary Patent Examiner · GS-14
- Service22 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsAEDER, SEAN E
Examiner Aeder can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Aeder
- The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 22.8 to 41.4 points.
- Plan for the timeline. First office action averages 742 days vs the 627-day USPTO norm.
- Expect a §103. Obviousness is the most-issued rejection (179), and applicants overcame it 41.4% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 12.5 to 23.7 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 26 winning responses to Examiner Aeder's §103 rejections that Boundly has classified, 20 (77%) amended the claims and argued, 4 argued without amending, and 2 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Aeder?
Draft your response with Examiner Aeder's record and Art Unit 1642's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 11.7% | 75.0% | 52.2% | +22.8pp |
| 2022 | 22.4% | 84.6% | 58.8% | +25.8pp |
| 2021 | 19.8% | 85.7% | 44.3% | +41.4pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Aeder.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 20.4% | 66.7% | 54.2% | +12.5pp |
| 2022 | 29.6% | 83.3% | 59.6% | +23.7pp |
| 2021 | 30.9% | 65.0% | 47.3% | +17.7pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/256556 | High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody | Patented | 1 | 🔒 View |
| 17/908291 | New Method and Compound for Prostate Cancer Diagnosis | Patented | 2 | 🔒 View |
| 19/384849 | IL-4R and TSLP Inhibitors and Methods of Use Thereof | Patented | 1 | 🔒 View |
| 17/666999 | Methods for Identifying and Treating High-Plasticity Cell State Driving Tumor Progression in Lung Cancer | Patented | 7 | 🔒 View |
Art Unit 1642 technology
Frequently asked questions
What is Examiner Sean E. Aeder's allowance rate?
Is Examiner Aeder a hard examiner?
Do examiner interviews help with Examiner Aeder?
What is Examiner Aeder's most common rejection?
Is an RCE worth filing with Examiner Aeder?
How long until the first office action from Examiner Aeder?
How do I contact Examiner Sean E. Aeder?
Put Examiner Aeder's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.